Constitutive Expression of Human Bcl-2 Modulates Nitrogen Mustard and Camptothecin Induced Apoptosis

Cancer Research

Volumn 53, Issue 8, 1993, Pages 1853-1861

  Hockenbery, D ^c   Korsmeyer, S J ^c   Kohn, K W ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CHLORMETHINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CROSS LINKING; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; DRUG MECHANISM; GENETIC TRANSFECTION; HUMAN; IMMUNOMODULATION; MITOSIS INHIBITION; MOUSE; PREVENTION; PRIORITY JOURNAL; PROTO ONCOGENE;

ANIMAL; APOPTOSIS; CAMPTOTHECIN; CELL CYCLE; CELL LINE; DNA DAMAGE; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; INTERLEUKIN-3; MECHLORETHAMINE; MICE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENES;

EID: 0027196091     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Haluska, F. G., Tsujimoto, Y., and Croce, C. M. Oncogene activation by chromosome translocation in human malignancy. Annu. Rev. Genet., 21: 321-345, 1987.
2. Yunis, J. J. The chromosomal basis of human neoplasia. Science (Washington DC), 221: 227-236, 1983.
3. Solomon, E., Borrow, J., and Goddard, A. D. Chromosomal aberrations and cancer. Science (Washington DC), 254: 1153-1160, 1991.
4. Levine, E. G., Arthur, D. C., Frizzera, G., Peterson, B. A., Hurd, D. D., and Bloomfield, C. D. There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkins lymphomas. Blood, 66: 1414-1422, 1985.
5. Weiss, L. M., Wamke, R. A., Sklar, J., and Cleary, M. L. Molecular analysis of the t(14: 18) chromosomal translocation in malignant lymphomas. N. Engl. J. Med., 317: 1185-1189, 1987.
6. Homing, S. J., and Rosenberg, S. A. The natural history of initially untreated low-grade non-Hodgkins lymphomas. N. Engl. J. Med., 311: 1471-1475, 1984.
7. Hubbard, S. M., Chabner, B. A., Devita, V. T., Simon, R., Berard, C. W., Jones, R. B., Garvin, A. J., Canellos, G. P., Osborne, C. K. and Young, R. C. Histologic progression in non-Hodgkin's lymphoma. Blood, 59: 258-264, 1982.
8. Yunis, J. J., Mayer, M. G., Amesen, M. A., Aeppli, D. P., Oken, M. M., and Frizzera, G. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N. Engl. J. Med., 320: 1047-1054, 1989.
9. Tsujimoto, Y., Finger, L. R., Yunis, J. J., Nowell, P. C., and Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14; 18) chromosome translocation. Science (Washington DC), 226: 1097-1099, 1984.
10. Bakhshi, A., Wright, J. J., Graninger, W., Seto, M., Owens, J., Cossman, J., Jensen, J. P., Goldman, P. and Korsmeyer, S. J. Mechanism of the t(14:18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners. Proc. Natl. Acad. Sci. USA, 84: 2396-2400, 1987.
11. Tsujimoto, Y., Gorham, J., Cossman, J., Jaffe, E., and Croce, C. The t(14: 18) chromosome translocation involved in B-cell neoplasms results from mistakes in VDJ joining. Science (Washington DC), 229: 1390-1393, 1985.
12. Bakhshi, A., Jensen, J. P., Goldman, P., Wright, J. J., McBride, O. W., Epstein, A. L., and Korsmeyer S. J. Cloning of the chromosomal breakpoint of t(14: 18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell, 41: 899-906, 1985.
13. Cleary, M. L., and Sklar, J. Nucleotide sequence of a t(14: 18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl. Acad. Sci. USA, 82: 7439-7443, 1985.
14. Cleary, M. L., Smith, S. D., and Sklar, J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2!immunoglobin transcript resulting from the t(14: 18) translocation. Cell, 47: 2537-2542, 1987.
15. Seto, M., Jaeger, U., Hockett, R. D., Graninger, W., Bennett. S., Goldman, P., and Korsmeyer, S. J. Alternative promoters and exons, somatic mutation and deregulation of the bcl-2-Ig fusion gene in lymphoma. EMBO J., 7: 123-131, 1988.
16. Graninger, W. B., Seto, M., Boutain, B., Goldman, P., and Korsmeyer, S. J. Expression of bcl-2 and bcl-2-lg fusion transcripts in normal and neoplastic cells. J. Clin. Invest., 80: 1512-1515, 1987.
17. Chen-Levy, Z., Nourse, J., and Cleary, M. L. The bcl-2 candidate proto-oncogene product is a 24-kilodalton intergral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14:18) translocation. Mol. Cell. Biol., 9: 701-710, 1989.
18. McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKeam, J. P., and Korsmeyer, S. J. #c/-2-immunoglobin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation. Cell, 57: 79-88, 1989.
19. McDonnell, T. J., and Korsmeyer, S. J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature (Lond.), 349: 254-256, 1991.
20. Nunez, G., Seto, M., Seremetis, S., Ferrero, D., Grignani, F., Korsmeyer, S. J., and Dalla-Favera, R. Growth and tumor-promoting effects of deregulated bcl-2 in human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA, 86: 4589-4593, 1989.
21. Tsujimoto, Y. Stress-resistance conferred by high level of bcl-2 protein in human B-lymphoblastoid cell. Oncogene, 4: 1331-1336, 1989.
22. Tsujimoto, Y. Overexpression of the human bcl-2 gene product results in growth enhancement of Epstein-Barr virus-immortalized B cells. Proc. Natl. Acad. Sci. USA, 86: 1958-1962, 1989.
23. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348: 334-336, 1990.
24. Vaux, D. L., Cory, S., and Adams, J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperation with c-mvc to immortalise pre-B cells. Nature (Lond.), 335: 440-442, 1988.
25. Nunez, G., London, L., Hockenbery, D., Alexander, M., McKeam, J. P., and Korsmeyer, S. J. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol., 144: 3602-3610, 1990.
26. Nunez, G., Hockenbery, D., McDonnell, T. J., Sorensen, C. M., and Korsmeyer, S. J. Bcl-2 maintains B cell memory. Nature (Lond.), 353: 71-73, 1991.
27. Strasser, A., Whittingham, S., Vaux, D. L., Bath, M. L., Adams, J. M., Cory, S., and Harris, A. W. Enforced bcl-2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl. Acad. Sci. USA, 88: 8661-8665, 1991.
28. Cross, M., and Dexter, T. M. Growth factors in development, transformation, and tumorigenesis. Cell, 64: 271-280, 1991.
29. Metcalf, D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature (Lond.), 339: 27-30, 1989.
30. Williams, G. T., Smith, C. A., Spooncer, E., Dexter, T. M., and Taylor, D. R. Haemopoitic colony stimulating factors promote cell survival by suppressing apoptosis. Nature (Lond.), 343: 76-79, 1990.
31. Duke, R. C., and Cohen, J. J. IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. Lymphokine Res., 5: 289-299, 1986.
32. Wyllie, A. H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (Lond.), 284: 555-556, 1980.
33. Kerr, J. F. R., and Harmon, B. V. Definition and incidence of apoptosis: an historical perspective. In: L. D. Tomei and F. O. Cope (eds.), Apoptosis: the Molecular Basis of Cell Death, pp. 5-29. New York: Cold Spring Harbor Laboratory Press, 1991.
34. Sentman, C. L., Shutter, J. R., Hockenbery, D., Kanagawa, O., and Korsmeyer, S. J. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell, 67: 879-888, 1991.
35. Alnemri, E. S., Fernandes, T. F., Haidar, S., Croce, C. M., and Litwack, G. Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B-leukemias. Cancer Res., 52: 491-495, 1992.
36. Henderson, S., Rowe, M., Gregory, C., Croom-Carter, D., Wang, F., Longnecker, R., Kieff, E., and Rickinson, A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 65: 1107-1115, 1991.
37. McKeam, J. P., McCubrey, J., and Fagg, B. Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors. Proc. Natl. Acad. Sci. USA, 82: 7414-7418, 1985.
38. Fuhlbrigge, R. C., Fine, S. M., Unanue, E. R., and Chaplin, D. D. Expression of membrane interleukin 1 by fibroblasts transfected with murine pro-interleukin 1 cDNA. Proc. Natl. Acad. Sci. USA, 85: 5649-5653, 1988.
39. Kohn, K. W. Principles and practice of DNA filter elution. Pharmacol. Ther., 49: 55-77, 1991.
40. O'Connor, P. M., and Kohn, K. W. Comparative pharmacokinetics of DNA lesion formation and removal following treatment of LI210 cells with nitrogen mustards. Cancer Commun., 2: 387-394, 1990.
41. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase 1. Cancer Res., 49: 5016-5022, 1989.
42. O'Connor, P. M., Kerrigan, D., Bertrand, R., Kohn, K. W., and Pommier, Y. 10, 11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells. Cancer Commun., 12: 395-400, 1990.
43. O'Connor, P. M., Wasserman, K., Sarang, M., Magrath, I., Bohr, V. A., and Kohn, K. W. Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res., 51: 6550-6557, 1991.
44. Judah, J. D., Ahmed, K., and McLean, A. G. Pathogenesis of cell necrosis. Fed. Proc. Am. Soc. Exp. Biol., 24: 12-17, 1965.
45. Zwelling, L. A., Michaels, S., Schwartz, H., Dobson, P. P., and Kohn, K. W. DNA cross-linking as an indicator of sensitivity and resistance of mouse LI210 leukemia to cis-Diamminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res., 41: 640-649, 1981.
46. Sorenson, C. M., Barry, M. A., and Eastman, A. Analysis of events associated with cell-cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst., 82: 749-755, 1990.
47. Dive, C. D., and Hickman, J. A. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer, 45: 192-196, 199.
48. Zhang, H., D'Arpa, P., and Liu, L. F. A model for tumor cell killing by topoisomerase poisons. Cancer Cells, 2: 23-27, 1990.
49. Del Bino, G., and Darzynkiewicz, Z. Camptothecin, teniposide, or 4'-(9-acridiny-lamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S-phase of HL-60 cells. Cancer Res., 51: 1165-1169, 1991.
50. Cotter, T. G., Glynn, J. M., Echeverri, F., and Green, D. R. The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cell cycle. Anticancer Res., 12: 773-780, 1992.
51. Yaw-Huei, Hsiang, Lihou, M. G., and Liu, L. F. Arrest of replication forks by drug stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
52. Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
53. Isfort, R., Huhn, R. D., Frackelton, A. R., and Ihle, J. N. Stimulation of factor-dependent myeloid cell lines with interleukin 3 induces tyrosine phosphorylation of several cellular substrates. J. Biol. Chem., 263: 19203-19209, 1988.
54. Farrar, W. L., Thomas, T. P., and Anderson, W. B. Altered cytosol/membrane enzyme redistribution on interleukin-3 activation of protein kinase C. Nature (Lond.), 315: 235-237, 1985.
55. Kaufmann, S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res., 49: 5870-5878, 1989.
56. Eastman, A. Activation of genetic program for cell death. Anticancer Drug Des., 6: 339, 1991.
57. Jones, D. P., McConkey, D. J., Nicotera, P., and Orrenius, S. Calcium-activated DNA fragmentation in rat liver nuclei. J. Biol. Chem., 264: 6398-6403, 1989.
58. Cohen, J. J., and Duke, R. C. Glucocorticoid activation of a calcium dependent endonuclease in thymocyte nuclei leads to cell death. J. Immunol., 132: 38-42, 1984.
59. Rodriguez-Tarduchy, G., Collins, M., and Lopez-Rivas, A. Regulation of apoptosis in interleukin-3-dependent hemopoietic cells by interleukin-3 and calcium inonophores. EMBO J., 9: 2997-3002, 1990.
60. Rodriguez-Tarduchy, G., Malde, P., Lopez-Rivas, A., and Collins, M. K. L. Inhibition of apoptosis by calcium ionophores in IL-3 dependent bone marrow cells is dependent upon production of IL-4. J. Immunol., 148: 1416-1422, 1992.